{"id":"anthracycline-dexamethasone-based-induction-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hyperglycemia (dexamethasone-related)"}]},"_chembl":{"chemblId":"CHEMBL1697787","moleculeType":"Small molecule","molecularWeight":"528.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anthracyclines (such as daunorubicin or doxorubicin) are topoisomerase II inhibitors that intercalate into DNA, causing strand breaks and preventing cancer cell proliferation. Dexamethasone, a corticosteroid, reduces inflammation and may enhance chemotherapy tolerability by suppressing immune activation. This combination is used as induction therapy in hematologic malignancies to achieve rapid cytoreduction.","oneSentence":"Anthracycline chemotherapy intercalates into DNA to prevent replication, while dexamethasone suppresses immune-mediated inflammation and enhances chemotherapy efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:07.501Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia induction therapy"},{"name":"Lymphoma induction therapy"}]},"trialDetails":[{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT02779283","phase":"PHASE1","title":"Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2016-01-13","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT01324180","phase":"PHASE1","title":"Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-07-18","conditions":"Acute Lymphoblastic Leukemia","enrollment":14},{"nctId":"NCT00025259","phase":"PHASE3","title":"Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-09","conditions":"Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","enrollment":1734},{"nctId":"NCT01490060","phase":"NA","title":"Fosaprepitant in Patients Receiving Ifosfamide-based Regimen","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05","conditions":"Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy","enrollment":47},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT00002665","phase":"PHASE2","title":"SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1995-07","conditions":"Leukemia, Neutropenia, Thrombocytopenia","enrollment":50},{"nctId":"NCT00613457","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2000-09","conditions":"Leukemia","enrollment":2039},{"nctId":"NCT02288741","phase":"PHASE3","title":"Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy","status":"COMPLETED","sponsor":"WiSP Wissenschaftlicher Service Pharma GmbH","startDate":"2001-08","conditions":"Multiple Myeloma","enrollment":549},{"nctId":"NCT00215943","phase":"PHASE3","title":"Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2003-06","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00430118","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2000-07","conditions":"Leukemia","enrollment":4559},{"nctId":"NCT00003728","phase":"PHASE3","title":"Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-12","conditions":"Leukemia, Lymphoma","enrollment":1500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ID, VAD, CAD"],"phase":"phase_3","status":"active","brandName":"Anthracycline/dexamethasone-based induction chemotherapy","genericName":"Anthracycline/dexamethasone-based induction chemotherapy","companyName":"WiSP Wissenschaftlicher Service Pharma GmbH","companyId":"wisp-wissenschaftlicher-service-pharma-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anthracycline chemotherapy intercalates into DNA to prevent replication, while dexamethasone suppresses immune-mediated inflammation and enhances chemotherapy efficacy. Used for Acute leukemia induction therapy, Lymphoma induction therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}